NCT02253251Recruiting
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Source: ClinicalTrials.gov · Last updated 23 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 15000 (estimated)
- First submitted
- 25 Sept 2014
- Start date
- Sept 2014
- Primary completion date
- Dec 2030
- Lead sponsor
- MiraKind
- Diseases
- Endometriosis, Ovarian cancer
- NCT number
- NCT02253251
What you commit to
- Study type: Observational
- Planned participants: 15000
- From Sept 2014 to the primary completion date, Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Younger than 18
Other
- Non-english speaking and unable to understand and sign the consent
Who the study is looking for
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MiraKind Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.